Business
Radiopharm Theranostics tanks on ASX debut – The Australian Financial Review
The paper value of chairman Paul Hopper’s 35.5 per cent stake fell from $54 million to $36 million in just a few hours.
The early stage company does not have revenue from licence arrangements or product sales. It is developing a platform of radiopharmaceutical products for diagnostic and therapeutic cancer treatment.
Shanghai-based NanoMab Technologies is the second-largest…
Continue Reading
-
Noosa News9 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
Noosa News15 hours agoLarge fleet of Robinson R22 helicopters sold as HM Air flies in another direction
-
General7 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
Noosa News8 hours agoLyka Doggie Date Night at Moonlight Cinema